Abstract
Immunosurveillance of cancer is well known. It is believed that escape from the immunosurveillance system and failure of the immunocytes to mount an adequate immune response lead to cancer. These and other evidences led to the development of immune checkpoint inhibitors that have taken the oncology field by storm. Despite these advances, only a fraction of patients with cancer are benefited by immune checkpoint inhibitors. Immunocytes including macrophages seem to release ROS and toxic lipid peroxides that have selective tumoricidal action. Essential fatty acids and their metabolites have a regulatory role not only in inflammation and immune response modulation but may also mediate the cytotoxic action of immunocytes and have a significant role in mutagenesis and carcinogenesis and assist in the elimination of cancer cells by radiation and chemotherapeutic drugs. Immune checkpoint inhibitors and CAR T (chimeric antigen receptor therapy) may work by delivering toxic lipid peroxides to tumor cells. Gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid are toxic tumor cells but not to normal cells, and thus they have specific anti-cancer action that needs to be exploited in the clinic.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rosser EC, Oleinika K, Tonon S, Doyle R, Bosma A, Carter NA, Harris KA, Jones SA, Klein N, Mauri C. Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production. Nat Med. 2014;20:1334–9.
Reigstad CS, Salmonson CE, Rainey JF 3rd, Szurszewski JH, Linden DR, Sonnenburg JL, Farrugia G, Kashyap PC. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J. 2015;29:1395–403.
Rojo D, Hevia A, Bargiela R, López P, Cuervo A, González S, et al. Ranking the impact of human health disorders on gut metabolism: systemic lupus erythematosus and obesity as study cases. Sci Rep. 2015;5:8310.
Lukens JR, Gurung P, Vogel P, Johnson GR, Carter RA, McGoldrick DJ, et al. Dietary modulation of the microbiome affects autoinflammatory disease. Nature. 2014;516:246–9.
Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59–64.
Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–6.
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.
Walker AW, Parkhill J. Fighting obesity with bacteria. Science. 2013;341:1069–70.
Das UN. Clinical laboratory tools to diagnose inflammation. Adv Clin Chem. 2006;41:189–229.
Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621–67.
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.
Pancer Z, Cooper MD. The evolution of adaptive immunity. Annu Rev Immunol. 2006;24:497–518.
Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787–93.
McHeyzer-Williams LJ, Malherbe LP, McHeyzer-Williams MG. Helper T cell-regulated B cell immunity. Curr Top Microbiol Immunol. 2006;311:59–83.
Holtmeier W, Kabelitz D. gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy. 2005;86:151–83.
Girardi M. Immunosurveillance and immunoregulation by gammadelta T cells. J Invest Dermatol. 2006;126:25–31.
Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res. 2009;69:599–608.
Golding A, Hasni S, Illei G, Shevach EM. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2013;65:2898–906.
Lü CX, Xu RD, Cao M, Wang G, Yan FQ, Shang SS, Wu XF, Ruan L, Quan XQ, Zhang CT. FOXP3 demethylation as a means of identifying quantitative defects in regulatory T cells in acute coronary syndrome. Atherosclerosis. 2013;229:263–70.
Jeron A, Hansen W, Ewert F, Buer J, Geffers R, Bruder D. ChIP-on-chip analysis identifies IL-22 as direct target gene of ectopically expressed FOXP3 transcription factor in human T cells. BMC Genomics. 2012;13:705.
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–8.
Burnet FM. Cancer—a biological approach: I. the processes of control. II. The significance of somatic mutation. Br Med J. 1957;1:779–86.
Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. J Immunol. 2007;121:1–14.
Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001;50:3–15.
De Simone V, Franzè E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F, Monteleone G, Stolfi C. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2014; https://doi.org/10.1038/onc.2014.286.
Peppicelli S, Bianchini F, Calorini L. Inflammatory cytokines induce vascular endothelial growth factor-C expression in melanoma-associated macrophages and stimulate melanoma lymph node metastasis. Oncol Lett. 2014;8:1133–8.
Giordano M, Roncagalli R, Bourdely P, Chasson L, Buferne M, Yamasaki S, Beyaert R, van Loo G, Auphan-Anezin N, Schmitt-Verhulst AM, Verdeil G. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc Natl Acad Sci U S A. 2014;111:11115–111120.
Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol. 2012;32:463–88.
Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Phys. 2012;228:1404–12.
Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65.
Kono Y, Kawakami S, Higuchi Y, Yamashita F, Hashida M. In vitro evaluation of inhibitory effect of nuclear factor-kappaB activity by small interfering RNA on pro-tumor characteristics of M2-like macrophages. Biol Pharm Bull. 2014;37:137–44.
Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux JP, Baud L. Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol. 1995;155:2077–84.
Kim JY, Lim K, Kim KH, Kim JH, Choi JS, Shim SC. N-3 polyunsaturated fatty acids restore Th17 and Treg balance in collagen antibody-induced arthritis. PLoS One. 2018;13:e0194331.
Bi X, Li F, Liu S, Jin Y, Zhang X, Yang T, Dai Y, Li X, Zhao AZ. ω-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity. J Clin Invest. 2017;127:1757–71.
Gu M, Li Y, Tang H, Zhang C, Li W, Zhang Y, Li Y, Zhao Y, Song C. Endogenous omega (n)-3 fatty acids in Fat-1 mice attenuated depression-like bhavior, imbalance between microglial M1 and M2 phenotypes, and dysfunction of neurotrophins induced by lipopolysaccharide administration. Nutrients. 2018;10:E1351.
Samuels JS, Holland L, López M, Meyers K, Cumbie WG, McClain A, Ignatowicz A, Nelson D, Shashidharamurthy R. Prostaglandin E2 and IL-23 interconnects STAT3 and RoRγ pathways to initiate Th17 CD4+ T-cell development during rheumatoid arthritis. Inflamm Res. 2018;67:589–96.
Ueharaguchi Y, Honda T, Kusuba N, Hanakawa S, Adachi A, Sawada Y, Otsuka A, Kitoh A, Dainichi T, Egawa G, Nakashima C, Nakajima S, Murata T, Ono S, Arita M, Narumiya S, Miyachi Y, Kabashima K. Thromboxane A2 facilitates IL-17A production from Vγ4+ γδ T cells and promotes psoriatic dermatitis in mice. J Allergy Clin Immunol. 2018;142:680–3.
Kim JH, Choi YJ, Lee BH, Song MY, Ban CY, Kim J, Park J, Kim SE, Kim TG, Park SH, Kim HP, Sung YC, Kim SC, Shin EC. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells. J Allergy Clin Immunol. 2016;137:1466–76.
Sawada Y, Honda T, Nakamizo S, Otsuka A, Ogawa N, Kobayashi Y, Nakamura M, Kabashima K. Resolvin E1 attenuates murine psoriatic dermatitis. Sci Rep. 2018;8:11873. https://doi.org/10.1038/s41598-018-30373-1.
Wang H, Zhao Q, Luo D, Yin Y, Li T, Zhao M. Resolvin E1 inhibits corneal allograft rejection in high-risk corneal transplantation. Invest Ophthalmol Vis Sci. 2018;59:3911–9.
Saito-Sasaki N, Sawada Y, Mashima E, Yamaguchi T, Ohmori S, Yoshioka H, Haruyama S, Okada E, Nakamura M. Maresin-1 suppresses imiquimod-induced skin inflammation by regulating IL-23 receptor expression. Sci Rep. 2018;8:5522.
Shi Q, Yin Z, Zhao B, Sun F, Yu H, Yin X, Zhang L, Wang S. PGE2 elevates IL-23 production in human dendritic cells via a cAMP dependent pathway. Mediat Inflamm. 2015;2015:984690.
Sheibanie AF, Tadmori I, Jing H, Vassiliou E, Ganea D. Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J. 2004;18:1318–20.
Kalim KW, Groettrup M. Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit. Mol Immunol. 2013;53:274–82.
Qian X, Gu L, Ning H, Zhang Y, Hsueh EC, Fu M, Hu X, Wei L, Hoft DF, Liu J. Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. J Immunol. 2013;190:5894–902.
Alvarez C, Amaral MM, Langellotti C, Vermeulen M. Leukotriene C(4) prevents the complete maturation of murine dendritic cells and modifies interleukin-12/interleukin-23 balance. Immunology. 2011;134:185–97.
Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol. 2008;9:873–9.
Maekawa T, Hosur K, Abe T, Kantarci A, Ziogas A, Wang B, Van Dyke TE, Chavakis T, Hajishengallis G. Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway. Nat Commun. 2015;6:8272.
Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765–72.
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261–8.
Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med. 2008;14:550–9.
Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.
Ankri C, Cohen CJ. Out of the bitter came forth sweet: activating CD28-dependent co-stimulation via PD-1 ligands. Onco Targets Ther. 2014;3:e27399.
Bettelli E, Kom T, Oukka M, Kuchroo VK. Induction and effector functions of TH17 cells. Nature. 2008;453:1051–7.
Margarita Dominguez-Villar M, Hafler DA. An innate role for IL-17. Science. 2011;332:47–8.
Sato K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203:2673–82.
Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171:6173–7.
Komiyama Y, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:566–73.
Chabaud M, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42:963–70.
Lock C, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8:500–8.
Fujino S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65–70.
Wilson NJ, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950–7.
Kebir H, et al. Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173–5.
Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–89.
Bettelli E, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–8.
Laurence A, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26:371–81.
Mucida D, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317:256–60.
Kleinschek MA, et al. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med. 2007;204:161–70.
Batten M, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 2006;7:929–36.
Stumhofer JS, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol. 2006;7:937–45.
Wang R, Hasnain SZ, Tong H, Das I, Che-Hao Chen A, Oancea I, Proctor M, Florin TH, Eri RD, McGuckin MA. Neutralizing IL-23 is superior to blocking IL-17 in suppressing intestinal inflammation in a spontaneous murine colitis Model. Inflamm Bowel Dis. 2015;21:973–84.
Lyson K, McCann SM. Involvement of arachidonic acid cascade pathways in interleukin-6-stimulated corticotropin-releasing factor release in vitro. Neuroendocrinology. 1992;55:708–13.
Lee IT, Lin CC, Cheng SE, Hsiao LD, Hsiao YC, Yang CM. TNF-α induces cytosolic phospholipase A2 expression in human lung epithelial cells via JNK1/2- and p38 MAPK-dependent AP-1 activation. PLoS One. 2013;8:e72783.
Spriggs DR, Sherman ML, Imamura K, Mohri M, Rodriguez C, Robbins G, Kufe DW. Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. Cancer Res. 1990;50:7101–7.
Jaulmes A, Thierry S, Janvier B, Raymondjean M, Maréchal V. Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta. FASEB J. 2006;20:1727–9.
Leslie CC. Cytosolic phospholipase A2: physiological function and role in disease. J Lipid Res. 2015;56:1386–402.
Bai M, Zhang L, Fu B, Bai J, Zhang Y, Cai G, Bai X, Feng Z, Sun S, Chen X. IL-17A improves the efficacy of mesenchymal stem cells in ischemic-reperfusion renal injury by increasing Treg percentages by the COX-2/PGE2 pathway. Kidney Int. 2018;93:814–25.
Shoda H, Yanai R, Yoshimura T, Nagai T, Kimura K, Sobrin L, Connor KM, Sakoda Y, Tamada K, Ikeda T, Sonoda KH. Dietary Omega-3 fatty acids suppress experimental autoimmune uveitis in association with inhibition of Th1 and Th17 cell function. PLoS One. 2015;10:e0138241.
Xu J, Duan X, Hu F, Poorun D, Liu X, Wang X, Zhang S, Gan L, He M, Zhu K, Ming Z, Chen H. Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways. J Dermatol Sci. 2018;89:127–35.
Rumzhum NN, Patel BS, Prabhala P, Gelissen IC, Oliver BG, Ammit AJ. IL-17A increases TNF-α-induced COX-2 protein stability and augments PGE2 secretion from airway smooth muscle cells: impact on β2 -adrenergic receptor desensitization. Allergy. 2016;71:387–96.
Zhang F, Koyama Y, Sanuki R, Mitsui N, Suzuki N, Kimura A, Nakajima A, Shimizu N, Maeno M. IL-17A stimulates the expression of inflammatory cytokines via celecoxib-blocked prostaglandin in MC3T3-E1 cells. Arch Oral Biol. 2010;55:679–88.
Tokuda H, Kozawa O, Uematsu T. Interleukin (IL)-17 enhances prostaglandin F(2 alpha)-stimulated IL-6 synthesis in osteoblasts. Prostaglandins Leukot Essent Fatty Acids. 2002;66:427–33.
Changchun K, Pengchao H, Ke S, Ying W, Lei W. Interleukin-17 augments tumor necrosis factor α-mediated increase of hypoxia-inducible factor-1α and inhibits vasodilator-stimulated phosphoprotein expression to reduce the adhesion of breast cancer cells. Oncol Lett. 2017;13:3253–60.
Henness S, Johnson CK, Ge Q, Armour CL, Hughes JM, Ammit AJ. IL-17A augments TNF-alpha-induced IL-6 expression in airway smooth muscle by enhancing mRNA stability. J Allergy Clin Immunol. 2004;114:958–64.
Naveen KVG, Naidu VGM, Das UN. Arachidonic acid and lipoxin A4 attenuate streptozotocin-induced cytotoxicity to RIN5F cells in vitro and type 1 and type 2 diabetes mellitus in vivo. Nutrition. 2017;35:61–80.
Hao W, Wong OY, Liu X, Lee P, Chen Y, Wong KK. ω-3 fatty acids suppress inflammatory cytokine production by macrophages and hepatocytes. J Pediatr Surg. 2010;45:2412–8.
Suzuki M, Noda K, Kubota S, Hirasawa M, Ozawa Y, Tsubota K, Mizuki N, Ishida S. Eicosapentaenoic acid suppresses ocular inflammation in endotoxin-induced uveitis. Mol Vis. 2010;16:1382–8.
Weylandt KH, Krause LF, Gomolka B, Chiu CY, Bilal S, Nadolny A, Waechter SF, Fischer A, Rothe M, Kang JX. Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-α. Carcinogenesis. 2011;32:897–903.
Das UN. Is there a role for bioactive lipids in the pathobiology of diabetes mellitus? Front Endocrinol (Lausanne). 2017;8:182.
Dooper MM, van Riel B, Graus YM, M’Rabet L. Dihomo-gamma-linolenic acid inhibits tumour necrosis factor-alpha production by human leucocytes independently of cyclooxygenase activity. Immunology. 2003;110:348–57.
Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-α. Nature. 2006;440:1054–9.
Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, Beattie MS, Malenka RC. Control of synaptic strength by glial TNFα. Science. 2002;295:2282–5.
Ribeira M, Brigas HC, Temido-Ferreira M, Pousinha PA, Regen T, Santa C, Coelho JE, Marques-Morgado I, Valente CA, Omenetti S, Stockinger B, Waisman A, Manadas B, Lopes LV, Silva-Santos B, Ribot JC. Meningeal γδ T cell–derived IL-17 controls synaptic plasticity and short-term memory. Sci Immunol. 2019;4:eaay5199.
Darios F, Davletov B. Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. Nature. 2006;440:813–7.
Gódor-Kacsándi A, Felszeghy K, Ranky M, Luiten PGM, Cs N. Developmental docosahexaenoic and arachidonic acid supplementation improves adult learning and increases resistance against excitotoxicity in the brain. Acta Physiol Hung. 2013;100L:186–96.
Pongrac JL, Slack PJ, Innis SM. Dietary polyunsaturated fat that is low in (n-3) and high in (n-6) fatty acids alters the SNARE protein complex and nitrosylation in rat hippocampus. J Nutr. 2007;137:1852–6.
Siresha B, Das UN. PUFAs, BDNF and lipoxin A4 inhibit chemical-induced cytotoxicity of RIN5F cells in vitro and streptozotocin-induced type 2 diabetes mellitus in vivo. Lipids Health Dis. 2019;18(1):214.
Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM, Wojcicki TR, Mailey E, Vieira VJ, Martin SA, Pence BD, Woods JA, McAuley E, Kramer AF. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108:3017–22.
Gangemi S, Luciotti G, D’Urbano E, Mallamace A, Santoro D, Bellinghieri G, Davi G, Romano M. Physical exercise increases urinary excretion of lipoxin A4 and related compounds. J Appl Physiol (1985). 2003;94:2237–40.
Luo CL, Li QQ, Chen XP, Zhang XM, Li LL, Li BX, Zhao ZQ, Tao LY. Lipoxin A4 attenuates brain damage and downregulates the production of pro-inflammatory cytokines and phosphorylated mitogen-activated protein kinases in a mouse model of traumatic brain injury. Brain Res. 2013;1502:1–10.
Romero LO, Massey AE, Mata-Daboin AD, Sierra-Valdez FJ, Chauhan SC, Cordero-Morales JF, Vásquez V. Dietary fatty acids fine-tune Piezo1 mechanical response. Nat Commun. 2019;10:1200. https://doi.org/10.1038/s41467-019-09055-7.
Accardi A. Lipids link ion channels and cancer. Science. 2015;349:789–90.
Rao VR, Perez-Neut M, Kaja S, Gentile S. Voltage-gated ion channels in cancer cell proliferation. Cancers. 2015;7:849–75.
Mochizuki-Oda N, Mori K, Negishi M, Ito S. Prostaglandin E2 activates Ca2+ channels in bovine adrenal chromaffin cells. J Neurochem. 1991;56:541–7.
Ge S, Hertel B, Susnik N, Rong S, Dittrich AM, Schmitt R, Haller H, von Vietinghoff S. Interleukin 17 receptor A modulates monocyte subsets and macrophage generation in vivo. PLoS One. 2014;9:e85461.
Zheng L, Chu J, Shi Y, Zhou X, Tan L, Li Q, Cui L, Han Z, Han Y, Fan D. Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17. Cell Biosci. 2013;3:46.
Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, Iwaisako K, Liu X, Zhang M, Österreicher CH, Stickel F, Ley K, Brenner DA, Kisseleva T. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012;143:765–776.e3.
Valente AJ, Yoshida T, Gardner JD, Somanna N, Delafontaine P, Chandrasekar B. Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1. Cell Signal. 2012;24:560–8.
Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S. Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum. 2011;63:3575–85.
Zhao L, Tang Y, You Z, Wang Q, Liang S, Han X, Qiu D, Wei J, Liu Y, Shen L, Chen X, Peng Y, Li Z, Ma X. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One. 2011;6:e18909.
Basha HI, Subramanian V, Seetharam A, Nath DS, Ramachandran S, Anderson CD, Shenoy S, Chapman WC, Crippin JS, Mohanakumar T. Characterization of HCV-specific CD4+Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis. Am J Transplant. 2011;11:775–85.
Feng W, Li W, Liu W, Wang F, Li Y, Yan W. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol. 2009;87:212–8.
Sommerfeld SD, Cherry C, Schwab RM, Chung L, Maestas DR Jr, Laffont P, Stein JE, Tam A, Ganguly S, Housseau F, Taube JM, Pardoll DM, Cahan P, Elisseeff JH. Interleukin-36γ-producing macrophages drive IL-17-mediated fibrosis. Sci Immunol. 2019;4:eaax4783. https://doi.org/10.1126/sciimmunol.aax4783.
Amara S, Lopez K, Banan B, Brown SK, Whalen M, Myles E, Ivy MT, Johnson T, Schey KL, Tiriveedhi V. Synergistic effect of pro-inflammatory TNFα and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosis. Mol Immunol. 2015;64:26–35.
Kurtoğlu EL, Kayhan B, Gül M, Kayhan B, Akdoğan Kayhan M, Karaca ZM, Yeşilada E, Yılmaz S. A bioactive product lipoxin A4 attenuates liver fibrosis in an experimental model by regulating immune response and modulating the expression of regeneration genes. Turk J Gastroenterol. 2019;30:745–57.
Bai Y, Wang J, He Z, Yang M, Li L, Jiang H. Mesenchymal stem cells reverse diabetic nephropathy disease via lipoxin A4 by targeting transforming growth factor β (TGF-β)/smad pathway and pro-inflammatory cytokines. Med Sci Monit. 2019;25:3069–76.
Yang Y, Hu L, Xia H, Chen L, Cui S, Wang Y, Zhou T, Xiong W, Song L, Li S, Pan S, Xu J, Liu M, Xiao H, Qin L, Shang Y, Yao S. Resolvin D1 attenuates mechanical stretch-induced pulmonary fibrosis via epithelial-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol. 2019;316:L1013–24.
Zheng S, D’Souza VK, Bartis D, Dancer RC, Parekh D, Naidu B, Gao-Smith F, Wang Q, Jin S, Lian Q, Thickett DR. Lipoxin A4 promotes lung epithelial repair whilst inhibiting fibroblast proliferation. ERJ Open Res. 2016;2(3):00079-2015. eCollection 2016 Jul.
Yatomi M, Hisada T, Ishizuka T, Koga Y, Ono A, Kamide Y, Seki K, Aoki-Saito H, Tsurumaki H, Sunaga N, Kaira K, Dobashi K, Yamada M, Okajima F. 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice. Physiol Rep. 2015;3:e12628.
Herrera BS, Kantarci A, Zarrough A, Hasturk H, Leung KP, Van Dyke TE. LXA4 actions direct fibroblast function and wound closure. Biochem Biophys Res Commun. 2015;464:1072–7.
Perciani CT, MacParland SA. Lifting the veil on macrophage diversity in tissue regeneration and fibrosis. Sci Immunol. 2019;4:eaaz0749.
Borbiro I, Badheka D, Rohacs T. Activation of TRPV1 channels inhibits mechanosensitive Piezo channel activity by depleting membrane phosphoinositides. Sci Signal. 2015;8:ra15.
Havemose-Poulsen A, Sørensen LK, Stoltze K, Bendtzen K, Holmstrup P. Cytokine profiles in peripheral blood and whole blood cell cultures associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. J Periodontol. 2005;76:2276–85.
Guimarães PM, Scavuzzi BM, Stadtlober NP, Franchi Santos LFDR, Lozovoy MAB, Iriyoda TMV, Costa NT, Reiche EMV, Maes M, Dichi I, Simão ANC. Cytokines in systemic lupus erythematosus: far beyond Th1/Th2 dualism lupus: cytokine profiles. Immunol Cell Biol. 2017;95:824–31.
Yoshida T, Ichikawa Y, Tojo T, Homma M. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904. Lupus. 1996;5:129–38.
Navarro E, Esteve M, Olivé A, Klaassen J, Cabré E, Tena X, Fernández-Bañares F, Pastor C, Gassull MA. Abnormal fatty acid pattern in rheumatoid arthritis. A rationale for treatment with marine and botanical lipids. J Rheumatol. 2000;27:298–303.
Suryaprabha P, Das UN, Ramesh G, Kumar KV, Kumar GS. Reactive oxygen species, lipid peroxides and essential fatty acids in patients with rheumatoid arthritis and systemic lupus erythematosus. Prostaglandins Leukot Essent Fatty Acids. 1991;43:251–5.
Mohan IK, Das UN. Oxidant stress, anti-oxidants and essential fatty acids in systemic lupus erythematosus. Prostaglandins Leukot Essent Fatty Acids. 1997;56:193–8.
Horrobin DF. Low prevalences of coronary heart disease (CHD), psoriasis, asthma and rheumatoid arthritis in Eskimos: are they caused by high dietary intake of eicosapentaenoic acid (EPA), a genetic variation of essential fatty acid (EFA) metabolism or a combination of both? Med Hypotheses. 1987;22:421–8.
Horrobin DF. Essential fatty acid metabolism in diseases of connective tissue with special reference to scleroderma and to Sjogren’s syndrome. Med Hypotheses. 1984;14:233–47.
Laitinen O, Seppalä E, Nissilä M, Vapaatalo H. Plasma levels and urinary excretion of prostaglandins in patients with rheumatoid arthritis. Clin Rheumatol. 1983;2:401–6.
Trang LE, Granström E, Lövgren O. Levels of prostaglandins F2 alpha and E2 and thromboxane B2 in joint fluid in rheumatoid arthritis. Scand J Rheumatol. 1977;6:151–4.
Egg D. Concentrations of prostaglandins D2, E2, F2 alpha, 6-keto-F1 alpha and thromboxane B2 in synovial fluid from patients with inflammatory joint disorders and osteoarthritis. Z Rheumatol. 1984;43:89–96.
Egg D, Günther R, Herold M, Kerschbaumer F. Prostaglandins E2 and F2 alpha concentrations in the synovial fluid in rheumatoid and traumatic knee joint diseases. Z Rheumatol. 1980;39:170–5.
Das UN. Lipoxins as biomarkers of lupus and other inflammatory conditions. Lipids Health Dis. 2011;10:76. https://doi.org/10.1186/1476-511X-10-76.
Das UN. Inflammatory bowel disease as a disorder of an imbalance between pro- and anti-inflammatory molecules and deficiency of resolution bioactive lipids. Lipids Health Dis. 2016;15:11. https://doi.org/10.1186/s12944-015-0165-4.
Das UN. Is multiple sclerosis a proresolution deficiency disorder? Nutrition. 2012;28:951–8.
Conte FP, Menezes-de-Lima O Jr, Verri WA Jr, Cunha FQ, Penido C, Henriques MG. Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects. Br J Pharmacol. 2010;161:911–24.
Chan MM, Moore AR. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J Immunol. 2010;184:6418–26.
Hashimoto A, Hayashi I, Murakami Y, Sato Y, Kitasato H, Matsushita R, Iizuka N, Urabe K, Itoman M, Hirohata S, Endo H. Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. J Rheumatol. 2007;34:2144–53.
Thomas E, Leroux JL, Blotman F, Chavis C. Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. Inflamm Res. 1995;44:121–4.
Zhang Y, Desai A, Yang SY, Bae KB, Antczak MI, Fink SP, et al. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science. 2015;348:aaa2340. https://doi.org/10.1126/science.aaa2340.
Tateishi N, Kaneda Y, Kakutani S, Kawashima H, Shibata H, Morita I. Dietary supplementation with arachidonic acid increases arachidonic acid content in paw, but does not affect arthritis severity or prostaglandin E2 content in rat adjuvant-induced arthritis model. Lipids Health Dis. 2015;14:3.
Tateishi N, Kakutani S, Kawashima H, Shibata H, Morita I. Dietary supplementation of arachidonic acid increases arachidonic acid and lipoxin A4 contents in colon but does not affect severity or prostaglandin E2 content in murine colitis model. Lipids Health Dis. 2014;13:30.
Naveen KVG, Naidu VGM, Das UN. Arachidonic acid and lipoxin A4 attenuate alloxan-induced cytotoxicity to RIN5F cells in vitro and type 1 diabetes mellitus in vivo. Biofactors. 2017;43:251–71.
Katoh T, Lakkis FG, Makita N, Badr KF. Co-regulated expression of glomerular 12/15-lipoxygenase and interleukin-4 mRNAs in rat nephrotoxic nephritis. Kidney Int. 1994;46:341–9.
Jiang C, Wang H, Xue M, Lin L, Wang J, Cai G, Shen Q. Reprograming of peripheral Foxp3+ regulatory T cell towards Th17-like cell in patients with active systemic lupus erythematosus. Clin Immunol. 2019;209:108267. https://doi.org/10.1016/j.clim.2019.108267.
Mohammadi S, Sedighi S, Memarian A. IL-17 is aberrantly overexpressed among under-treatment Systemic Lupus Erythematosus patients. Iran J Pathol. 2019;14:236–42.
Nordin F, Shaharir SS, Abdul Wahab A, Mustafar R, Abdul Gafor AH, Mohamed Said MS, Rajalingham S, Shah SA. Serum and urine interleukin-17A levels as biomarkers of disease activity in systemic lupus erythematosus. Int J Rheum Dis. 2019;22:1419–26.
Zhang Q, Liu S, Ge D, Cunningham DM, Huang F, Ma L, Burris TP, You Z. Targeting Th17-IL-17 pathway in prevention of micro-invasive prostate cancer in a mouse model. Prostate. 2017;77:888–99.
Zhang Q, Liu S, Parajuli KR, Zhang W, Zhang K, Mo Z, Liu J, Chen Z, Yang S, Wang AR, Myers L, You Z. Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene. 2017;36:687–99.
Wang B, Zhao CH, Sun G, Zhang ZW, Qian BM, Zhu YF, Cai MY, Pandey S, Zhao D, Wang YW, Qiu W, Shi L. IL-17 induces the proliferation and migration of glioma cells through the activation of PI3K/Akt1/NF-κB-p65. Cancer Lett. 2019;447:93–104.
Zhang Y, Wang ZC, Zhang ZS, Chen F. MicroRNA-155 regulates cervical cancer via inducing Th17/Treg imbalance. Eur Rev Med Pharmacol Sci. 2018;22:3719–26.
Akbay EA, Koyama S, Liu Y, Dries R, Bufe LE, Silkes M, et al. Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. J Thorac Oncol. 2017;12:1268–79.
Liu CSC, Raychaudhuri D, Paul B, Chakrabarty Y, Ghosh AR, Rahaman O, Talukdar A, Ganguly D. Piezo1 mechanosensors optimize human T cell activation. J Immunol. 2018;200:1255–60.
Chandy KG, Norton RS. Channelling potassium to fight cancer. Nature. 2016;537:497–8.
Ordway R, Walsh JV Jr, Singer JJ. Arachidonic acid and other fatty acids directly activate potassium channels in smooth muscle cells. Science. 1989;244:1176–9.
Kim D, Clapham DE. Potassium channels in cardiac cells activated by arachidonic acid and phospholipids. Science. 1989;244:1174–6.
Amoroso S, Schmid-Antomarchi H, Fosset M, Lazdunskit M. Glucose, sulfonylureas, and neurotransmitter release: role of ATP-sensitive K+ channels. Science. 1990;247:852–4.
Isaacs JT. Prostate cancer takes nerve. Science. 2013;341:134–5.
Hayakawa Y, Wang TC. Nerves switch on angiogenic metabolism. Science. 2017;358:305–6.
Barria A. Dangerous liaisons as tumours form synapses with neuron. Nature. 2019;573:499–501.
Walev I, Klein J, Husmann M, Valeva A, Strauch S, Wirtz H, Weichel O, Bhakdi S. Potassium regulates IL-1β processing via calcium-independent phospholipase A2. J Immunol. 2000;164:5120–4.
Walev I, Reskel K, Palmer M, Valeva A, Bhakdi S. Potassium-inhibited processing of IL-1β in human monocytes. EMBO J. 1995;14:1607–14.
Hughes FM Jr, Bortner CD, Purdy GD, Cidlowski JA. Intracellular K+ suppresses the activation of apoptosis in lymphocytes. J Biol Chem. 1997;272:30567–76.
Das UN. Molecular basis of health and disease. New York: Springer; 2011.
Das UN, Padma MC. Prostaglandins in lymphocyte transformation. J Assoc Physicians India. 1978;26:503–6.
Das UN. Prostaglandins and immune response in cancer. Int J Tiss Reac. 1980;2:233–6.
Das UN. Inhibition of sensitized lymphocyte response to sperm antigen(s) by prostaglandins. IRCS Med Sci. 1981;9:1087.
Kumar SG, Das UN, Kumar KV, Madhavi DNP, Tan BKH. Effect of n-6 and n-3 fatty acids on the proliferation and secretion of TNF and IL-2 by human lymphocytes in vitro. Nutr Res. 1992;12:815–23.
Kumar SG, Das UN. Effect of prostaglandins and their precursors on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and various interleukins. Prostaglandins Leukot Essent Fatty Acids. 1994;50:331–4.
Das UN. HLA-DR expression, cytokines and bioactive lipids in sepsis. Arch Med Sci. 2014;10(2):325–35.
Narumiya S. Physiology and pathophysiology of prostanoid receptors. Proc Jpn Acad Ser B. 2007;83:296–319.
Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983;3:295–315.
Betz M, Fox BS. Prostaglandin E2 inhibits production of TH1 lymphokines but not of Th2 lymphokines. J Immunol. 1991;146:108–13.
Gold KN, Weyand CM, Goronzy JJ. Modulation of helper T cell function by prostaglandins. Arthritis Rheum. 1994;37:925–33.
Hilkens CM, et al. Differential modulation of T helper type 1 (TH1) and T helper type 2 (TH2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur J Immunol. 1995;25:59–63.
Yao C, Sakata D, Esaki Y, et al. Prostaglandin E2–EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat Med. 2009;15:633–40.
Kabashima K, et al. Prostaglandin E2–EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med. 2003;9:744–9.
Herve M, et al. Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in schistosome immune evasion. Eur J Immunol. 2003;33:2764–72.
Kabashima K, et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol. 2003;4:694–701.
Chizzolini C, et al. Prostaglandin E2 synergistically with interleukin-23 favors human TH17 expansion. Blood. 2008;112:3696–703.
Boniface K, et al. Prostaglandin E2 regulates TH17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009;206:535–48.
Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23:144–50.
Kalinski P. Regulation of immune responses by prostaglandin e2. J Immunol. 2012;188:21–8.
Linnemeyer PA, Pollack SB. Prostaglandin E2-induced changes in the phenotype, morphology, and lytic activity of IL-2-activated natural killer cells. J Immunol. 1993;150:3747–54.
Sreeramkumar V, Fresno M, Cuesta N. Prostaglandin E2 and T cells: friends or foes? Immunol Cell Biol. 2012;90:579–86.
Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med. 1994;180:2365–70.
Demeure CE, Yang LP, Desjardins C, Raynauld P, Delespesse G. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines. Eur J Immunol. 1997;27:3526–31.
Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.
Rahmouni S, et al. Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirus-induced T-cell dysfunction in mice. Biochem J. 2004;384:469–76.
Owen K, Gomolka D, Droller MJ. Production of prostaglandin E2 by tumor cells in vitro. Cancer Res. 1980;40:3167–71.
Young MR, Knies S. Prostaglandin E production by Lewis lung carcinoma: mechanism for tumor establishment in vivo. J Natl Cancer Inst. 1984;72:919–22.
Balch CM, Dougherty PA, Cloud GA, Tilden AB. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery. 1984;95:71–7.
Murray JL, Kollmorgen GM. Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma. J Clin Immunol. 1983;3:268–76.
Passwell J, Levanon M, Davidsohn J, Ramot B. Monocyte PGE2 secretion in Hodgkin’s disease and its relation to decreased cellular immunity. Clin Exp Immunol. 1983;51:61–8.
Chiabrando C, Broggini M, Castagnoli MN, Donelli MG, Noseda A, Visintainer M, Garattini S, Fanelli R. Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth. Cancer Res. 1985;45:3605–8.
McLemore TL, Hubbard WC, Litterst CL, Liu MC, Miller S, McMahon NA, Eggleston JC, Boyd MR. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1988;48:3140–247.
Fulton AM. Inhibition of experimental metastasis with indomethacin: role of macrophages and natural killer cells. Prostaglandins. 1988;35:413–25.
Maxwell WJ, Kelleher D, Keating JJ, Hogan FP, Bloomfield FJ, MacDonald GS, Keeling PW. Enhanced secretion of prostaglandin E2 by tissue-fixed macrophages in colonic carcinoma. Digestion. 1990;47:160–6.
Baxevanis CN, Reclos GJ, Gritzapis AD, Dedousis GV, Missitzis I, Papamichail M. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer. 1993;72:491–501.
Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol. 1994;153:1674–86.
Liu XH, Connolly JM, Rose DP. Eicosanoids as mediators of linoleic acid-stimulated invasion and type IV collagenase production by a metastatic human breast cancer cell line. Clin Exp Metastasis. 1996;14:145–52.
Li S, Xu X, Jiang M, Bi Y, Xu J, Han M. Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway. Mol Med Rep. 2015;11:4454–62.
Kim MJ, Kim HS, Lee SH, Yang Y, Lee MS, Lim JS. NDRG2 controls COX-2/PGE2-mediated breast cancer cell migration and invasion. Mol Cells. 2014;37:759–65.
Zhang M, Zhang H, Cheng S, Zhang D, Xu Y, Bai X, Xia S, Zhang L, Ma J, Du M, Wang Y, Wang J, Chen M, Leng J. Prostaglandin E2 accelerates invasion by upregulating snail in hepatocellular carcinoma cells. Tumour Biol. 2014;35:7135–45.
Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol. 2006;207:261–70.
Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem. 2005;280:24053–63.
Xu L, Han C, Wu T. A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth. J Biol Chem. 2006;281:33982–96.
Misra UK, Pizzo SV. Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways. PLoS One. 2013;8:e63150.
Evans DB, Thavarajah M, Kanis JA. Involvement of prostaglandin E2 in the inhibition of osteocalcin synthesis by human osteoblast-like cells in response to cytokines and systemic hormones. Biochem Biophys Res Commun. 1990;167:194–202.
Hori T, Yamanaka Y, Hayakawa M, Shibamoto S, Tsujimoto M, Oku N, Ito F. Prostaglandins antagonize fibroblast proliferation stimulated by tumor necrosis factor. Biochem Biophys Res Commun. 1991;174:758–66.
Kambayashi T, Alexander HR, Fong M, Strassmann G. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol. 1995;154:3383–90.
Takigawa M, Takashiba S, Takahashi K, Arai H, Kurihara H, Murayama Y. Prostaglandin E2 inhibits interleukin-6 release but not its transcription in human gingival fibroblasts stimulated with interleukin-1 beta or tumor necrosis factor-alpha. J Periodontol. 1994;65:1122–7.
Fieren MW, van den Bemd GJ, Ben-Efraim S, Bonta IL. Prostaglandin E2 inhibits the release of tumor necrosis factor-alpha, rather than interleukin 1 beta, from human macrophages. Immunol Lett. 1992;31:85–90.
Vassiliou E, Jing H, Ganea D. Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells. Cell Immunol. 2003;223:120–32.
Stafford JB, Marnett LJ. Prostaglandin E2 inhibits tumor necrosis factor-alpha RNA through PKA type I. Biochem Biophys Res Commun. 2008;366:104–9.
Xu XJ, Reichner JS, Mastrofrancesco B, Henry WL Jr, Albina JE. Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production. J Immunol. 2008;180:2125–31.
Huang CN, Liu KL, Cheng CH, Lin YS, Lin MJ, Lin TH. PGE2 enhances cytokine-elicited nitric oxide production in mouse cortical collecting duct cells. Nitric Oxide. 2005;12:150–8.
Gaillard T, Mülsch A, Klein H, Decker K. Regulation by prostaglandin E2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages. Biol Chem Hoppe Seyler. 1992;373:897–902.
Stadler J, Harbrecht BG, Di Silvio M, Curran RD, Jordan ML, Simmons RL, Billiar TR. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukoc Biol. 1993;53:165–72.
Tetsuka T, Daphna-Iken D, Miller BW, Guan Z, Baier LD, Morrison AR. Nitric oxide amplifies interleukin 1-induced cyclooxygenase-2 expression in rat mesangial cells. J Clin Invest. 1996;97:2051–6.
Wilson KT, Vaandrager AB, De Vente J, Musch MW, De Jonge HR, Chang EB. Production and localization of cGMP and PGE2 in nitroprusside-stimulated rat colonic ion transport. Am J Phys. 1996;270(3 Pt 1):C832–40.
Sautebin L, Ialenti A, Ianaro A, Di Rosa M. Endogenous nitric oxide increases prostaglandin biosynthesis in carrageenin rat paw oedema. Eur J Pharmacol. 1995;286:219–22.
Biondi C, Fiorini S, Pavan B, Ferretti ME, Barion P, Vesce F. Interactions between the nitric oxide and prostaglandin E2 biosynthetic pathways in human amnion-like WISH cells. J Reprod Immunol. 2003;60:35–52.
Du Y, Sarthy VP, Kern TS. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol. 2004;287:R735–41.
Chien CC, Shen SC, Yang LY, Chen YC. Prostaglandins as negative regulators against lipopolysaccharide, lipoteichoic acid, and peptidoglycan-induced inducible nitric oxide synthase/nitric oxide production through reactive oxygen species-dependent heme oxygenase 1 expression in macrophages. Shock. 2012;38:549–58.
Stæhr M, Hansen PB, Madsen K, Vanhoutte PM, Nüsing RM, Jensen BL. Deletion of cyclooxygenase-2 in the mouse increases arterial blood pressure with no impairment in renal NO production in response to chronic high salt intake. Am J Physiol Regul Integr Comp Physiol. 2013;304:R899–907.
Harizi H, Norbert G. Inhibition of IL-6, TNF-alpha, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells. Cell Immunol. 2004;228:99–109.
Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol. 2002;168:2255–63.
Kanda N, Koike S, Watanabe S. IL-17 suppresses TNF-alpha-induced CCL27 production through induction of COX-2 in human keratinocytes. J Allergy Clin Immunol. 2005;116:1144–50.
Khayrullina T, Yen JH, Jing H, Ganea D. In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J Immunol. 2008;181:721–35.
Chen H, Qin J, Wei P, Zhang J, Li Q, Fu L, Li S, Ma C, Cong B. Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells. Prostaglandins Leukot Essent Fatty Acids. 2009;80:195–200.
Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A. 1993;90:7240–4.
Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol. 1995;114:1335–42.
Mollace V, Colasanti M, Muscoli C, Lauro GM, Iannone M, Rotiroti D, Nistico G. The effect of nitric oxide on cytokine-induced release of PGE2 by human cultured astroglial cells. Br J Pharmacol. 1998;124:742–6.
Marcinkiewicz J. Regulation of cytokine production by eicosanoids and nitric oxide. Arch Immunol Ther Exp. 1997;45:163–7.
Tanaka M, Ishibashi H, Hirata Y, Miki K, Kudo J, Niho Y. Tumor necrosis factor production by rat Kupffer cells-regulation by lipopolysaccharide, macrophage activating factor and prostaglandin E2. J Clin Lab Immunol. 1996;48:17–31.
Liu XH, Kirschenbaum A, Lu M, Yao S, Klausner A, Preston C, Holland JF, Levine AC. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun. 2002;290:249–55.
Reznikov LL, Kim SH, Westcott JY, Frishman J, Fantuzzi G, Novick D, Rubinstein M, Dinarello CA. IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci U S A. 2000;97:2174–9.
Perkins DJ, Kniss DA. Blockade of nitric oxide formation down-regulates cyclooxygenase-2 and decreases PGE2 biosynthesis in macrophages. J Leukoc Biol. 1999;65:792–9.
Sakurai T, Tamura K, Kogo H. Vascular endothelial growth factor increases messenger RNAs encoding cyclooxygenase-II and membrane-associated prostaglandin E synthase in rat luteal cells. J Endocrinol. 2004;183:527–33.
Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF, Wolfe MM. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. 2003;63:586–92.
Sailaja P, Mani AM, Naveen KVG, Anasuya DH, Siresha B, Das UN. Effect of polyunsaturated fatty acids and their metabolites on bleomycin-induced cytotoxic action on human neuroblastoma cells in vitro. PLoS One. 2014;9:e114766.
Santoro MG, Crisari A, Benedetto A, Amici C. Modulation of the growth of a human erythroleukemic cell line (K562) by prostaglandins: antiproliferative action of prostaglandin A. Cancer Res. 1986;46(12 Pt 1):6073–7.
de Bittencourt PI Jr, Miyasaka CK, Curi R, Williams JF. Effects of the antiproliferative cyclopentenone prostaglandin A1 on glutathione metabolism in human cancer cells in culture. Biochem Mol Biol Int. 1998;45:1255–64.
Sakai T, Yamaguchi N, Shiroko Y, Sekiguchi M, Fujii G, Nishino H. Prostaglandin D2 inhibits the proliferation of human malignant tumor cells. Prostaglandins. 1984;27:17–26.
Booyens J, Englebrecht P, Le Roux S, Louwrens CC, Van der Merwe CF, Katzeff IE. Some effects of the essential fatty acids linoleic acid, alpha-linolenic acid, and of their metabolites gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid and of prostaglandins A and E on the proliferation of human osteogenic sarcoma cells in culture. Prostaglandins Leukot Med. 1984;15:15–33.
Begin ME, Das UN, Ells G, Horrobin DF. Selective killing of human cancer cells by polyunsaturated fatty acids. Prostaglandins Leukot Med. 1985;19:177–86.
Begin ME, Ells G, Das UN, Horrobin DF. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst. 1986;77:1053–62.
Das UN. Tumoricidal action of cis-unsaturated fatty acids and their relationship to free radicals and lipid peroxidation. Cancer Lett. 1991;56:235–43.
Sagar PS, Das UN, Koratkar R, Ramesh G, Padma M, Kumar GS. Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells: relationship to free radicals and lipid peroxidation and its modulation by calmodulin antagonists. Cancer Lett. 1992;63:189–98.
Kumar GS, Das UN. Free radical-dependent suppression of growth of mouse myeloma cells by α-linolenic and eicosapentaenoic acids in vitro. Cancer Lett. 1995;92:27–38.
Padma M, Das UN. Effect of cis-unsaturated fatty acids on cellular oxidant stress in macrophage tumor (AK-5) cells in vitro. Cancer Lett. 1996;109:63–75.
Seigel I, Liu TL, Yaghoubzadeh E, Kaskey TS, Gleicher N. Cytotoxic effects of free fatty acids on ascites tumor cells. J Natl Cancer Inst. 1987;78:271–7.
Tolnai S, Morgan JF. Studies on the in vitro anti-tumor activity of fatty acids. V. Unsaturated fatty acids. Can J Biochem Physiol. 1962;40:869–75.
Monjazeb AM, High KP, Connoy A, Hart LS, Koumenis C, Chilton FH. Arachidonic acid-induced gene expression in colon cancer cells. Carcinogenesis. 2006;27:1950–60.
Monjazeb AM, High KP, Koumenis C, Chilton FH. Inhibitors of arachidonic acid metabolism act synergistically to signal apoptosis in neoplastic cells. Prostaglandins Leukot Essent Fatty Acids. 2005;73:463–74.
Canuto RA, Muzio G, Bassi AM, Maggiora M, Leonarduzzi G, Lindahl R, Dianzani MU, Ferro M. Enrichment with arachidonic acid increases the sensitivity of hepatoma cells to the cytotoxic effects of oxidative stress. Free Radic Biol Med. 1995;18:287–93.
Piazzi G, D’Argenio G, Prossomariti A, Lembo V, Mazzone G, Candela M, Biagi E, Brigidi P, Vitaglione P, Fogliano V, D’Angelo L, Fazio C, Munarini A, Belluzzi A, Ceccarelli C, Chieco P, Balbi T, Loadman PM, Hull MA, Romano M, Bazzoli F, Ricciardiello L. Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on notch signaling and gut microbiota. Int J Cancer. 2014;135:2004–13.
Sauer LA, Dauchy RT, Blask DE, Krause JA, Davidson LK, Dauchy EM. Eicosapentaenoic acid suppresses cell proliferation in MCF-7 human breast cancer xenografts in nude rats via a pertussis toxin-sensitive signal transduction pathway. J Nutr. 2005;135:2124–9.
Gu Z, Wu J, Wang S, Suburu J, Chen H, Thomas MJ, Shi L, Edwards IJ, Berquin IM, Chen YQ. Polyunsaturated fatty acids affect the localization and signaling of PIP3/AKT in prostate cancer cells. Carcinogenesis. 2013;34:1968–75.
Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM, Chen YQ. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis. 2012;33:404–12.
Blanckaert V, Ulmann L, Mimouni V, Antol J, Brancquart L, Chénais B. Docosahexaenoic acid intake decreases proliferation, increases apoptosis and decreases the invasive potential of the human breast carcinoma cell line MDA-MB-231. Int J Oncol. 2010;36:737–42.
Collett ED, Davidson LA, Fan YY, Lupton JR, Chapkin RS. n-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am J Physiol Cell Physiol. 2001;280:C1066–75.
Appel MJ, Woutersen RA. Dietary fish oil (MaxEPA) enhances pancreatic carcinogenesis in azaserine-treated rats. Br J Cancer. 1996;73:36–43.
Das UN. Tuning free radical metabolism to kill tumor cells selectively with emphasis on the interaction(s) between essential fatty acids, free radicals, lymphokines and prostaglandins. Ind J Pathol Microbiol. 1990;33:94–103.
Das UN. Cis-unsaturated fatty acids as potential anti-mutagenic, tumoricidal and anti-metastatic agents. Asia Pacific J Pharmacol. 1992;7:305–27.
Galeotti T, Borrello S, Masoti L. Oxy radical sources, scavenger systems and membrane damage in cancer cells. In: Das DK, Essman R, editors. Oxygen radicals: systemic events and disease processes. Basel: S. Karger; 1990. p. 129–48.
Dianzani MU, Rossi MA. Lipid peroxidation in tumors. In: Pani P, Feo F, Columbano A, Cagliari ESA, editors. Recent trends in chemical carcinogenesis, vol. 1. Italy: Cagliari; 1981. p. 243–57.
Bartoli GM, Galeotti T. Growth-related lipid peroxidation in tumor microsomal membranes and mitochondria. Biochim Biophys Acta. 1979;574:537–41.
Hostetler KY, Zenner BD, Morris HP. Phospholipid content of mitochondrial and microsomal membranes from Morris hepatomas of varying growth rates. Cancer Res. 1979;39:2978–83.
Hartz JW, Morton RE, Waite MM, Morris HP. Correlation of fatty acyl composition of mitochondrial and microsomal phospholipid with growth rate of rat hepatomas. Lab Invest. 1982;46:73–8.
Cheeseman KH, Emery S, Maddix SP, Slater TF, Burton GW, Ingold K. Studies on lipid peroxidation in normal and tumour tissue. The Yoshida rat liver tumour. Biochem J. 1988;250:247–52.
Cheeseman KH, Burton GW, Ingold KU, Slater TF. Lipid peroxidation and lipid antioxidants in normal and tumor cells. Toxicol Pathol. 1984;12:235–9.
Borrello S, Minotti G, Galeotti T. Factors influencing O2 and t-Bu OOH-dependent lipid peroxidation of tumor microsomes. In: Rotilio G, editor. Superoxide and superoxide dismutase in chemistry, biology and medicine. Amsterdam: Elsevier; 323, 1988. p. 324.
Das UN, Begin ME, Ells G, Huang YS, Horrobin DF. Polyunsaturated fatty acids augment free radical generation in tumor cells in vitro. Biochem Biophys Res Commun. 1987;145:15–24.
Das UN, Huang YS, Begin ME, Ells G, Horrobin DF. Uptake and distribution of cis-unsaturated fatty acids and their effect on free radical generation in normal and tumor cells in vitro. Free Radical Biol Med. 1987;3:9–14.
Bendetti A. Loss of lipid peroxidation as a histochemical marker for preneoplastic hepatocellular foci of rats. Cancer Res. 1984;44:5712–7.
Dunbar LM, Bailey JM. Enzyme deletions and essential fatty acid metabolism in cultured cells. J Biol Chem. 1975;250:1152–3.
Morton RE, Hartz JW, Reitz RC, Waite BM, Morris H. The acyl-CoA desaturases of microsomes from rat liver and the Morris 7777 hepatoma. Biochim Biophys Acta. 1979;573:321–31.
Nassar BA, Das UN, Huang YS, Ells G, Horrobin DF. The effect of chemical hepatocarcinogenesis on liver phospholipid composition in rats fed n-6 and n-3 fatty acid-supplemented diets. Proc Soc Exp Biol Med. 1992;199:365–8.
Das UN. Essential fatty acids- a review. Curr Pharm Biotechnol. 2006;7:467–82.
Das UN. Essential fatty acids: biochemistry, physiology, and pathology. Biotechnol J. 2006;1:420–39.
Serhan CN, Arita M, Hong S, Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids. 2004;39:1125–32.
Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196:1025–37.
Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192:1197–204.
Serhan CN, Takano T, Chiang N, Gronert K, Clish CB. Formation of endogenous “antiinflammatory” lipid mediators by transcellular biosynthesis. Lipoxins and aspirin-triggered lipoxins inhibit neutrophil recruitment and vascular permeability. Am J Respir Crit Care Med. 2000;161(2 Pt 2):S95–S101.
Cummings KB, Robertson RP. Prostaglandin: increased production by renal cell carcinoma. J Urol. 1977;118:720–3.
Hong SL, Wheless CM, Levine L. Elevated prostaglandins synthetase activity in methylcholanthrene-transformed mouse BALB/3T3. Prostaglandins. 1977;13:271–9.
Ylikorkala O, Kauppila A, Viinikka L. Effect of cytostatics on prostaglandin F2 alpha prostacyclin, and thromboxane in patients with gynecologic malignancies. Obstet Gynecol. 1981;58:483–6.
Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 1980;64:1061–70.
Trevisani A, Ferretti E, Capuzzo A, Tomasi V. Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumour growth by non-steroidal anti-inflammatory drugs. Br J Cancer. 1980;41:341–7.
Young MR, Newby M. Enhancement of Lewis lung carcinoma cell migration by prostaglandin E2 produced by macrophages. Cancer Res. 1986;46:160–4.
Cyran J, Lea MA, Lysz TW. Prostaglandin biosynthetic capacity of hepatomas with different growth rates. Int J Biochem. 1989;21:445–51.
LeFever A, Funahashi A. Elevated prostaglandin E2 levels in bronchoalveolar lavage fluid of patients with bronchogenic carcinoma. Chest. 1990;98:1397–402.
Qiao L, Kozoni V, Tsioulias GJ, Koutsos MI, Hanif R, Shiff SJ, Rigas B. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta. 1995;1258:215–23.
Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res. 2002;62:403–8.
Oberley LW, Buettner G. Role of SOD in cancer. A review. Cancer Res. 1979;39:1141–9.
Tisdale MJ, Mahmoud MD. Activities of free radical metabolizing enzymes in tumours. Br J Cancer. 1983;47:809–12.
Bize IB, Oberley LW, Morris HP. Superoxide dismutase and superoxide radical in Morris hepatomas. Cancer Res. 1980;40:3686–93.
Hendrickse CW, Kelly RW, Radley S, Donovan IA, Keighley MR, Neoptolemos JP. Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg. 1994;81:1219–23.
Jang YC, Remmen VH. The mitochondrial theory of aging: insight from transgenic and knockout mouse models. Exp Gerontol. 2009;44:256–60.
Gorman A, McGowan A, Cotter TG. Role of peroxide and superoxide anion during tumour cell apoptosis. FEBS Lett. 1997;404:27–33.
Li M, Beg AA. Induction of necrotic-like cell death by tumor necrosis factor alpha and caspase inhibitors: novel mechanism for killing virus-infected cells. J Virol. 2000;74:7470–7.
Huang TT, Carlson EJ, Raineri I, Gillespie AM, Kozy H, Epstein CJ. The use of transgenic and mutant mice to study oxygen free radical metabolism. Ann NY Acad Sci. 1999;893:95–112.
Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 3rd ed. Oxford: Oxford University Press; 1999.
Panaretakis T, Shabalina IG, Grandér D, Shoshan MC, DePierre JW. Reactive oxygen species and mitochondria mediate the induction of apoptosis in human hepatoma HepG2 cells by the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid. Toxicol Appl Pharmacol. 2001;173:56–64.
Hampton MB, Fadeel B, Orrenius S. Redox regulation of the caspases during apoptosis. Ann N Y Acad Sci. 1998;854:328–35.
Jacobson MD, Raff MC. Programmed cell death and Bcl-2 protection in very low oxygen. Nature. 1995;374:814–6.
Pervaiz S, Ramalingam JK, Hirpara JL, Clément MV. Superoxide anion inhibits drug-induced tumor cell death. FEBS Lett. 1999;459:343–8.
Wagner BA, Buettner GR, Oberley LW, Burns CP. Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species. Cancer Res. 1998;58:2809–16.
Arakaki N, Kajihara T, Arakaki R, Ohnishi T, Kazi JA, Nakashima H, Daikuhara Y. Involvement of oxidative stress in tumor cytotoxic activity of hepatocyte growth factor/scatter factor. J Biol Chem. 1999;274:13541–6.
Tamatani M, Ogawa S, Nuñez G, Tohyama M. Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Cell Death Differ. 1998;5:911–9.
Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R, Griffin JD. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999;93:2928–35.
Zimmerman RJ, Marafino BJ Jr, Chan A, Landre P, Winkelhake JL. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. Implications for mechanisms of action. J Immunol. 1989;142:1405–9.
Godfrey RW, Johnson WJ, Hoffstein ST. Recombinant tumor necrosis factor and interleukin-1 both stimulate human synovial cell arachidonic acid release and phospholipid metabolism. Biochem Biophys Res Commun. 1987;142:235–41.
Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162:2163–8.
Nara K, Odagiri H, Fujii M, Yamanaka Y, Yokoyama M, Morita T, Sasaki M, Kon M, Abo T. Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma. Cancer Immunol Immunother. 1987;25:126–32.
Neale ML, Fiera RA, Matthews N. Involvement of phospholipase A2 activation in tumour cell killing by tumour necrosis factor. Immunology. 1988;64:81–5. Hepburn A, Boeynaems JM, Fiers W, Dumont JE. Modulation of tumor necrosis factor-alpha cytotoxicity in L929 cells by bacterial toxins, hydrocortisone and inhibitors of arachidonic acid metabolism. Biocehem Biophys Res Commun 1987; 149: 815–22.
Suffys P, Beyaert R, Van Roy F, Fiers W. Reduced tumour necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism. Biochem Biophys Res Commun. 1987;149:735–43.
Matthews N, Neale ML, Jackson SK, Stark JM. Tumour cell killing by tumour necrosis factor: inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism. Immunology. 1987;62:153–5.
Berkow RL, Wang D, Larrick JW, Dodson RW, Howard TH. Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor. J Immunol. 1987;139:3783–91.
Talmadge JE, Bowersox O, Tribble H, Lee SH, Shepard HM, Liggitt D. Toxicity of tumor necrosis factor is synergistic with gamma-interferon and can be reduced with cyclooxygenase inhibitors. Am J Pathol. 1987;128:410–25.
Hori T, Kashiyama S, Hayakawa M, Shibamoto S, Tsujimoto M, Oku N, Ito F. Tumor necrosis factor is cytotoxic to human fibroblasts in the presence of exogenous arachidonic acid. Exp Cell Res. 1989;185:41–9.
Hayakawa M, Oku N, Takagi T, Hori T, Shibamoto S, Yamanaka Y, Takeuchi K, Tsujimoto M, Ito F. Involvement of prostaglandin-producing pathway in the cytotoxic action of tumor necrosis factor. Cell Struct Funct. 1991;16:333–40.
Das UN, Padma M, Sagar PS, Ramesh G, Koratkar R. Stimulation of free radical generation in human leukocytes by various agents including tumor necrosis factor is a calmodulin dependent process. Biochem Biophys Res Commun. 1990;167:1030–6.
Palombella VJ, Vilcek J. Mitogenic and cytotoxic actions of tumor necrosis factor in BALB/c 3T3 cells. Role of phospholipase activation. J Biol Chem. 1989;264:18128–36.
Reid T, Ramesha CS, Ringold GM. Resistance to killing by tumor necrosis factor in an adipocyte cell line caused by a defect in arachidonic acid biosynthesis. J Biol Chem. 1991;266:16580–6.
Chang DJ, Ringold GM, Heller RA. Cell killing and induction of manganous superoxide dismutase by tumor necrosis factor-alpha is mediated by lipoxygenase metabolites of arachidonic acid. Biochem Biophys Res Commun. 1992;188:538–46.
Fletcher JR, Collins JN, Graves ED 3rd, Luterman A, Williams MD, Izenberg SD, Rodning CB. Tumor necrosis factor-induced mortality is reversed with cyclooxygenase inhibition. Ann Surg. 1993;217:668–74.
Hayakawa M, Ishida N, Takeuchi K, Shibamoto S, Hori T, Oku N, Ito F, Tsujimoto M. Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor. J Biol Chem. 1993;268:11290–5.
West M, Mhatre M, Ceballos A, Floyd RA, Grammas P, Gabbita SP, Hamdheydari L, Mai T, Mou S, Pye QN, Stewart C, West S, Williamson KS, Zemlan F, Hensley K. The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem. 2004;91:133–43.
Kovaríková M, Hofmanová J, Soucek K, Kozubík A. The effects of TNF-alpha and inhibitors of arachidonic acid metabolism on human colon HT-29 cells depend on differentiation status. Differentiation. 2004;72:23–31.
Vento R, D’Alessandro N, Giuliano M, Lauricella M, Carabillo M, Tesoriere G. Induction of apoptosis by arachidonic acid in human retinoblastoma Y79 cells: involvement of oxidative stress. Exp Eye Res. 2000;70:503–17.
Sagar PS, Das UN. Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells in vitro. Prostaglandins Leukot Essent Fatty Acids. 1995;53:287–99.
Lin PS, Kwock L, Goodchild NT. Copper chelator enhancement of bleomycin cytotoxicity. Cancer. 1980;46:2360–4.
Werts ED, Gould MN. Relationships between cellular superoxide dismutase and susceptibility to chemically induced cancer in the rat mammary gland. Carcinogenesis. 1986;7:1197–201.
Cameron DJ. Suppression or enhancement by superoxide dismutase of tumor cell killing by macrophages of normal donors and breast cancer patients. Jpn J Exp Med. 1986;56:135–40.
Kawaguchi T, Takeyasu A, Matsunobu K, Uda T, Ishizawa M, Suzuki K, Nishiura T, Ishikawa M, Taniguchi N. Stimulation of Mn-superoxide dismutase expression by tumor necrosis factor-alpha: quantitative determination of Mn-SOD protein levels in TNF-resistant and sensitive cells by ELISA. Biochem Biophys Res Commun. 1990;171:1378–86.
Cervantes A, Pinedo HM, Lankelma J, Schuurhuis GJ. The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells. Cancer Lett. 1988;41:169–77.
Mimnaugh EG, Dusre L, Atwell J, Myers CE. Differential oxygen radical susceptibility of adriamycin-sensitive and -resistant MCF-7 human breast tumor cells. Cancer Res. 1989;49:8–15.
Huang C, Wu M. Superoxide dismutase activity in tissues from 19 cases of hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi. 1990;70:138–9.
Han YH, Kim SH, Kim SZ, Park WH. Antimycin A as a mitochondrial electron transport inhibitor prevents the growth of human lung cancer A549 cells. Oncol Rep. 2008;20:689–93.
Malafa M, Margenthaler J, Webb B, Neitzel L, Christophersen M. MnSOD expression is increased in metastatic gastric cancer. J Surg Res. 2000;88:130–4.
Westman NG, Marklund SL. Copper-and zinc-containing superoxide dismutase and manganese-containing superoxide dismutase in human tissues and human malignant tumors. Cancer Res. 1981;41:2962–6.
Zhong W, Oberley LW, Oberley TD, St Clair DK. Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene. 1997;14:481–90.
Toh Y, Kuninaka S, Oshiro T, Ikeda Y, Nakashima H, Baba H, Kohnoe S, Okamura T, Mori M, Sugimachi K. Overexpression of manganese superoxide dismutase mRNA may correlate with aggressiveness in gastric and colorectal adenocarcinomas. Int J Oncol. 2000;17:107–12.
Izutani R, Asano S, Imano M, Kuroda D, Kato M, Ohyanagi H. Expression of manganese superoxide dismutase in esophageal and gastric cancers. J Gastroenterol. 1998;33:816–22.
Zhong W, Yan T, Lim R, Oberley LW. Expression of superoxide dismutases, catalase, and glutathione peroxidase in glioma cells. Free Rad Biol Med. 1999;27:1334–45.
Huang Y, He T, Domann FE. Decreased expression of manganese superoxide dismutase in transformed cells is associated with increased cytosine methylation of the SOD2 gene. DNA Cell Biol. 1999;18:643–52.
Clement MV, Pervaiz S. Reactive oxygen intermediates regulate cellular apoptosis response to apoptotic stimuli: an hypothesis. Free Rad Biol Med. 1999;30:247–52.
Saunders JA, Rogers LC, Klomsiri C, Poole LB, Daniel LW. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med. 2010;49:2058–67.
Li M, Zhao L, Liu J, Liu A, Jia C, Ma D, Jiang Y, Bai X. Multi-mechanisms are involved in reactive oxygen species regulation of mTORC1 signaling. Cell Signal. 2010;22:1469–76.
Das UN. Essential fatty acids enhance free radical generation and lipid peroxidation to induce apoptosis of tumor cells. Clin Lipidol. 2011;6:463–89.
Das UN. Oxy radicals and their clinical implications. Curr Sci. 1993;65:964–8.
Das UN. Free radicals: biology and relevance to disease. J Assoc Physicians India. 1990;38:495–8.
Halliwell BA. Superway to kill cancer cells? Nat Med. 2000;6:1105–6.
Morisaki N, Lindsey JA, Stitts JM, Zhang H, Cornwell DG. Fatty acid metabolism and cell proliferation. V. Evaluation of pathways for the generation of lipid peroxides. Lipids. 1984;19:381–94.
Morisaki N, Sprecher H, Milo GE, Cornwell DG. Fatty acid specificity in the inhibition of cell proliferation and its relationship to lipid peroxidation and prostaglandin biosynthesis. Lipids. 1982;17:893–9.
Liepkalns VA, Icard-Liepkalns C, Cornwell DG. Regulation of cell division in a human glioma cell clone by arachidonic acid and alpha-tocopherol quinone. Cancer Lett. 1982;15:173–8.
Cheeseman KH, Collins M, Maddix S, Milia A, Proudfoot K, Slater TF, Burton GW, Webb A, Inglod KU. Lipid peroxidation in regenerating rat liver. FEBS Lett. 1986;209:191–6.
Slater TF, Cheeseman KH, Benedetto C, Collins M, Emery S, Maddix S, Nodes JT, Proudfoot K, Burton GW, Ingold KU. Studies on the hyperplasia (‘regeneration’) of the rat liver following partial hepatectomy. Changes in lipid peroxidation and general biochemical aspects. Biochem J. 1990;265:51–9.
Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995;14:3–15.
Martinez JD, Pennington ME, Craven MT, Warters RL, Cress AE. Free radicals generated by ionizing radiation signal nuclear translocation of p53. Cell Growth Differ. 1997;8:941–9.
Uberti D, Yavin E, Gil S, Ayasola KR, Goldfinger N, Rotter V. Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin. Brain Res Mol Brain Res. 1999;65:167–75.
Kitamura Y, Ota T, Matsuoka Y, Tooyama I, Kimura H, Shimohama S, Nomura Y, Gebicke-Haerter PJ, Taniguchi T. Hydrogen peroxide-induced apoptosis mediated by p53 protein in glial cells. Glia. 1999;25:154–64.
Pani G, Bedogni B, Anzevino R, Colavitti R, Palazzotti B, Borrello S, Galeotti T. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. Cancer Res. 2000;60:4654–60.
Hilf R, Murant RS, Narayana U, Gibson SL. Relationship of mitochondrial function and cellular adenosine triphosphate levels to hematoporphyrin derivative-induced photosensitization in R 3230 AC mammary tumors. Cancer Res. 1986;46:211–7.
Lee Y, Shacter E. Hydrogen peroxide inhibits activation, not activity, of cellular caspase-3 in vivo. Free Radic Biol Med. 2000;29:684–92.
Saretzki G, von Zglinicki T. Replicative senescence as a model of aging: the role of oxidative stress and telomere shortening-an overview. Z Gerontol Geriatr. 1999;32:69–75.
Oikawa S, Kawanishi S. Site-specific DNA damage at GGG sequence by oxidative stress may accelerate telomere shortening. FEBS Lett. 1999;453:365–8.
von Zglinicki T, Pilger R, Sitte N. Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med. 2000;28:64–74.
Ludlow AT, Spangenburg EE, Chin ER, Cheng WH, Roth SM. Telomeres shorten in response to oxidative stress in mouse skeletal muscle fibers. J Gerontol A Biol Sci Med Sci. 2014;69:821–30.
von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. 2002;27:339–44.
Romano GH, Harari Y, Yehuda T, Podhorzer A, Rubinstein L, Shamir R, Gottlieb A, Silberberg Y, Pe’er D, Ruppin E, Sharan R, Kupiec M. Environmental stresses disrupt telomere length homeostasis. PLoS Genet. 2013;9:e1003721.
Tyurina YY, Tyurina VA, Certa G, Quinn PJ, Schor NF, Kagan VE. Direct evidence for antioxidant effect of BCL-2 in PC 12 rat pheochromocytoma cells. Arch Biochem Biophys. 1997;344:413–23.
Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994;54:2095–7.
Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 1995;92:4507–11.
Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75:241–51.
Das UN. Essential fatty acids, lipid peroxidation and apoptosis. Prostaglandins Leukotrienes Essen Fatty Acids. 1999;61:157–63.
Padma M, Das UN. Effect of cis-unsaturated fatty acids on the activity of protein kinases and protein phosphorylation in macrophage tumor (AK-5) cells in vitro. Prostaglandins Leukotrienes Essen Fatty Acids. 1999;60:55–63.
Esposti MD, Hatzinisiriou I, McLennan H, Ralph S. Bcl-2 and mitochondrial oxygen radicals. New approaches with reactive oxygen species-sensitive probes. J Biol Chem. 1999;274:29831–7.
Steinman HM. The Bcl-2 oncoprotein functions as a pro-oxidant. J Biol Chem. 1995;270:3487–90.
Howard S, Bottino C, Brooke S, Cheng E, Giffard RG, Sapolsky R. Neuroprotective effects of bcl-2 overexpression in hippocampal cultures: interactions with pathways of oxidative damage. J Neurochem. 2002;83:914–23.
Virgili F, Santini MP, Canali R, Polakowska RR, Haake A, Perozzi G. Bcl-2 overexpression in the HaCaT cell line is associated with a different membrane fatty acid composition and sensitivity to oxidative stress. Free Radic Biol Med. 1998;24:93–101.
Sailaja P, Dwarakanath BS, Das UN. Arachidonic acid activates extrinsic apoptotic pathway to enhance tumoricidal action of bleomycin against IMR-32 cells. Prostaglandins Leukot Essent Fatty Acids. 2018;132:16–22.
Naveen KVG, Das UNN. Amelioration of streptozotocin-induced type 2 diabetes mellitus in Wistar rats by arachidonic acid. Biochem Biophys Res Commun. 2018;496:105–13.
Etienne-Mannevillea S, Lammerding J. Connecting the plasma membrane to the nucleus by intermediate filaments. Mole Biol Cell. 2017;28:695–6.
McGowan SE, Jackson SK, Doro MM, Olson PJ. Peroxisome proliferators alter lipid acquisition and elastin gene expression in neonatal rat lung fibroblasts. Am J Phys. 1997;273(6 Pt 1):L1249–57.
Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer. 2000;89:983–94.
Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000;407:390–5.
Das UN. A radical approach to cancer. Med Sci Monit. 2002;8:RA79–92.
Ge Y, Byun JS, De Luca P, Gueron G, Yabe IM, Sadiq-Ali SG, Figg WD, Quintero J, Haggerty CM, Li QQ, De Siervi A, Gardner K. Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol. Mol Pharmacol. 2008;74:872–83.
Colquhoun A. Mechanisms of action of eicosapentaenoic acid in bladder cancer cells in vitro: alterations in mitochondrial metabolism, reactive oxygen species generation and apoptosis induction. J Urol. 2009;181:1885–93.
Naidu MR, Das UN, Kishan A. Intratumoral gamma-linoleic acid therapy of human gliomas. Prostaglandins Leukot Essent Fatty Acids. 1992;45:181–4.
Das UN, Prasad VV, Reddy DR. Local application of gamma-linolenic acid in the treatment of human gliomas. Cancer Lett. 1995;94:147–55.
Bakshi A, Mukherjee D, Bakshi A, Banerji AK, Das UN. Gamma-linolenic acid therapy of human gliomas. Nutrition. 2003;19:305–9.
Das UN. Gamma-linolenic acid therapy of human glioma-a review of in vitro, in vivo, and clinical studies. Med Sci Monit. 2007;13:RA119–RA31.
Reddy DR, Prasad VS, Das UN. Intratumoural injection of gamma linolenic acid in malignant gliomas. J Clin Neurosci. 1998;5:36–9.
Smith DL, Willis AL, Mahmud I. Eicosanoid effects on cell proliferation in vitro: relevance to atherosclerosis. Prostaglandins Leukot Med. 1984;16:1–10.
Das UN. Lipoxins, resolvins, protectins, maresins and nitrolipids and their clinical implications with specific reference to cancer: part I. Clin Lipidol. 2013;8:437–63.
Rossi MA, Cecchini G. Lipid peroxidation in hepatomas of different degrees of deviation. Cell Biochem Function. 1983;1:49–54.
Burlakova EB, Palmina NP. On the possible role of free radical mechanism on the regulation of cell replication. Biofizika. 1967;12:82–8.
Gonzalez M, Schemmel R, Dugan L, Gray J, Welsch C. Dietary fish oil inhibits human breast carcinoma growth: a function of increased lipid peroxidation. Lipids. 1993;28:827–32.
Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci U S A. 2000;97:11280–5.
Brekke OL, Sagen E, Bjerve KS. Specificity of endogenous fatty acid release during tumor necrosis factor-induced apoptosis in WEHI 164 fibrosarcoma cells. J Lipid Res. 1999;40:2223–33.
Ramesh G, Das UN. Effect of free fatty acids on two stage skin carcinogenesis in mice. Cancer Lett. 1996;100:199–209.
Calviello G, Palozza O, Piccioni E, Maggiano N, Frattucci A, Franceschelli P, Bartoli GM. Supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. Int J Cancer. 1998;75:699–705.
Chapkin RS, Jiang YH, Davidson LA, Lupton JR. Modulation of intracellular second messengers by dietary fat during colonic tumor development. Adv Exp Med Biol. 1997;422:85–96.
Roynette CE, Calder PC, Dupertuis YM, Pichar C. n-3 Polyunsaturated fatty acids and colon cancer prevention. Clin Nutr. 2004;23:139–51.
Calviello G, Di Nicuolo F, Gragnoli S, Piccioni E, Serini S, Maggiano N, Tringali G, Navarra P, Ranelletti FO, Palozza P. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2induced ERK-1 and -2 and HIF-1α induction pathway. Carcinogenesis. 2004;25:2303–10.
Yu H, Liu Y, Pan W, Shen S, Das UN. Polyunsaturated fatty acids augment tumoricidal action of 5-fluorouracil on gastric cancer cells by their action on vascular endothelial growth factor, tumor necrosis factor-α and lipid metabolism related factors. Arch Med Sci. 2015;11(2):282–91.
Cai J, Jiang WG, Mansel RE. Inhibition of angiogenic factor- and tumor-induced angiogenesis by gamma linolenic acid. Prostaglandins Leukot Essen Fatty Acids. 1999;60:21–9.
Rose DP, Connolly JM. Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int J Oncologia. 1999;15:1011–5.
Jin Y, Arita M, Zhang Q, Saban DR, Chauhan SK, Chiang N, Serhan CN, Dana R. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci. 2009;50:4743–52.
Polavarapu S, Dwarakanath BS, Das UN. Differential action of polyunsaturated fatty acids and eicosanoids on bleomycin-induced cytotoxicity to neuroblastoma cells and lymphocytes. Arch Med Sci. 2018;14:207–29.
Hao H, Liu M, Wu P, Cai L, Tang K, Yi P, Li Y, Chen Y, Ye D. Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Lett. 2011;309:85–94.
Vieira AM, Neto EH, Figueiredo CC, Barja Fidalgo C, Fierro IM, Morandi V. TL-1, a synthetic analog of lipoxin, modulates endothelial permeability and interaction with tumor cells through a VEGF-dependent mechanism. Biochem Pharmacol. 2014;90:388–96.
Brigatte P, Faiad OJ, Ferreira Nocelli RC, Landgraf RG, Palma MS, Cury Y, Curi R, Sampaio SC. Walker 256 tumor growth suppression by crotoxin involves formyl peptide receptors and lipoxin A4. Mediat Inflamm. 2016;2016:2457532.
Schlager SI, Ohanian SH. Correlation between lipid synthesis in tumor cells and their sensitivity to humoral immune attack. Science. 1977;197:773–6.
Schlager SI, Ohanian SH, Borsos T. Correlation between the ability of tumor cells to incorporate specific fatty acids and their sensitivity to killing by a specific antibody plus guinea pig complement. J Natl Cancer Inst. 1978;61:931–4.
Schlager SI, Ohanian SH. Modulation of tumor cell susceptibility to humoral immune killing through chemical and physical manipulation of cellular lipid and fatty acid composition. J Immunol. 1980;125:1196–200.
Schlager SI, Madden LD, Meltzer MS, Bara S, Mamula MJ. Role of macrophage lipids in regulating tumoricidal activity. Cell Immunol. 1983;77:52–68.
Schlager SI, Meltzer MS, Madden LD. Role of membrane lipids in the immunological killing of tumor cells: II. Effector cell lipids. Lipids. 1983;18:483–8.
Schlager SI, Ohanian SH. Role of membrane lipids in the immunological killing of tumor cells: I. Target cell lipids. Lipids. 1983;18:475–82.
Schlager SI, Meltzer MS. Role of macrophage lipids in regulating tumoricidal activity. II. Internal genetic and external physiologic regulatory factors controlling macrophage tumor cytotoxicity also control characteristic lipid changes associated with tumoricidal cells. Cell Immunol. 1983;80:10–9.
Bell HS, Wharton SB, Leaver HA, Whittle IR. Effects of N-6 essential fatty acids on glioma invasion and growth: experimental studies with glioma spheroids in collagen gels. J Neurosurg. 1999;91:989–96.
Leaver HA, Wharton SB, Bell HS, Leaver-Yap IM, Whittle IR. Highly unsaturated fatty acid induced tumour regression in glioma pharmacodynamics and bioavailability of gamma linolenic acid in an implantation glioma model: effects on tumour biomass, apoptosis and neuronal tissue histology. Prostaglandins Leukot Essent Fatty Acids. 2002;67:283–92.
Benadiba M, Miyake JA, Colquhoun A. Gamma-linolenic acid alters Ku80, E2F1, and bax expression and induces micronucleus formation in C6 glioma cells in vitro. IUBMB Life. 2009;61:244–51.
Rohrbach S. Effects of dietary polyunsaturated fatty acids on mitochondria. Curr Pharm Des. 2009;15:4103–16.
Tuo Y, Wang D, Li S, Chen C. Long-term exposure of INS-1 rat insulinoma cells to linoleic acid and glucose in vitro affects cell viability and function through mitochondrial-mediated pathways. Endocrine. 2011;39:128–38.
Das UN. Arachidonic acid and lipoxin A4 as possible anti-diabetic molecules. Prostaglandins Leukot Essent Fatty Acids. 2013;88:201–10.
Kaviarasan K, Mohanlal J, Mohammad Mulla MA, Shanmugam S, Sharma T, Das UN, Angayarkanni N. Low blood and vitreal BDNF, LXA4 and altered Th1/Th2 cytokine balance as potential risk factors for diabetic retinopathy. Metabolism. 2015;64:958–66.
Zeghichi-Hamri S, de Lorgeril M, Salen P, Chibane M, de Leiris J, Boucher F, Laporte F. Protective effect of dietary n-3 polyunsaturated fatty acids on myocardial resistance to ischemia-reperfusion injury in rats. Nutr Res. 2010;30:849–57.
Sangeetha PS, Das UN. Gamma-linolenic acid and eicosapentaenoic acid potentiate the cytotoxicity of anti-cancer drugs on human cervical carcinoma (HeLa) cells in vitro. Med Sci Res. 1993;21:457–9.
Hagopian K, Weber KL, Hwee DT, Van Eenennaam AL, López-Lluch G, Villalba JM, Burón I, Navas P, German JB, Watkins SM, Chen Y, Wei A, McDonald RB, Ramsey JJ. Complex I-associated hydrogen peroxide production is decreased and electron transport chain enzyme activities are altered in n-3 enriched fat-1 mice. PLoS One. 2010;5:e12696.
Kansal S, Negi AK, Kaur R, Sarotra P, Sharma G, Aggarwal R, Agnihotri N. Evaluation of the role of oxidative stress in chemopreventive action of fish oil and celecoxib in the initiation phase of 7,12-dimethyl benz(α)anthracene-induced mammary carcinogenesis. Tumour Biol. 2011;32:167–77.
Dymkowska D, Wojtczak L. Arachidonic acid-induced apoptosis in rat hepatoma AS-30D cells is mediated by reactive oxygen species. Acta Biochim Pol. 2009;56:711–5.
Ribeiro G, Benadiba M, de Oliveira SD, Colquhoun A. The novel ruthenium-gamma-linolenic complex [Ru(2)(aGLA)(4)Cl] inhibits C6 rat glioma cell proliferation and induces changes in mitochondrial membrane potential, increased reactive oxygen species generation and apoptosis in vitro. Cell Biochem Funct. 2010;28:15–23.
Giros A, Grzybowski M, Sohn VR, Pons E, Fernandez-Morales J, Xicola RM, Sethi P, Grzybowski J, Goel A, Boland CR, Gassull MA, Llor X. Regulation of colorectal cancer cell apoptosis by the n-3 polyunsaturated fatty acids Docosahexaenoic and Eicosapentaenoic. Cancer Prev Res (Phila). 2009;2:732–42.
Ponnala S, Rao KP, Chaudhury JR, Ahmed J, Rama Rao B, Kanjilal S, Hasan Q, Das UN. Effect of polyunsaturated fatty acids on diphenyl hydantoin-induced genetic damage in vitro and in vivo. Prostaglandins Leukot Essent Fatty Acids. 2009;80:43–50.
Das UN, Rao KP. Effect of gamma-linolenic acid and prostaglandins E1 on gamma-radiation and chemical-induced genetic damage to the bone marrow cells of mice. Prostaglandins Leukot Essent Fatty Acids. 2006;74:165–73.
Das UN, Ramadevi G, Rao KP, Rao MS. Prostaglandins and their precursors can modify genetic damage-induced by gamma-radiation and benzo(a)pyrene. Prostaglandins. 1985;29:911–20.
Das UN. Tumoricidal and anti-angiogenic actions of gamma-linolenic acid and its derivatives. Curr Pharm Biotechnol. 2006;7:457–66.
Dhayal S, Morgan NG. Pharmacological characterization of the cytoprotective effects of polyunsaturated fatty acids in insulin-secreting BRIN-BD11 cells. Br J Pharmacol. 2011;162:1340–50.
Suresh Y, Das UN. Long-chain polyunsaturated fatty acids and chemically induced diabetes mellitus: effect of omega-6 fatty acids. Nutrition. 2003;19:93–114.
Suresh Y, Das UN. Long-chain polyunsaturated fatty acids and chemically induced diabetes mellitus. Effect of omega-3 fatty acids. Nutrition. 2003;19:213–28.
Bazan NG. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr Opin Clin Nutr Metab Care. 2007;10:136–41.
Madhavi N, Das UN. Reversal of KB-3-1 and KB-Ch-8-5 tumor cell drug-resistance by cis-unsaturated fatty acids in vitro. Med Sci Res. 1994;22:689–92.
Madhavi N, Das UN. Effect of n-6 and n-3 fatty acids on the survival of vincristine sensitive and resistant human cervical carcinoma cells in vitro. Cancer Lett. 1994;84:31–41.
Das UN, Madhavi N, Sravan Kumar G, Padma M, Sangeetha P. Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites? Prostaglandins Leukot Essent Fatty Acids. 1998;58:39–54.
Germain E, Chajès V, Cognault S, Lhuillery C, Bougnoux P. Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int J Cancer. 1998;75:578–83.
Mahéo K, Vibet S, Steghens JP, Dartigeas C, Lehman M, Bougnoux P, Goré J. Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med. 2005;39:742–51.
Ilc K, Ferrero JM, Fischel JL, Formento P, Bryce R, Etienne MC, Milano G. Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell lines. Anti-Cancer Drugs. 1999;10:413–7.
Menendez JA, Ropero S, Lupu R, Colomer R. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: relationship to lipid peroxidation and HER-2/neu expression. Oncol Rep. 2004;11:1241–52.
Menéndez JA, Ropero S, del Barbacid MM, Montero S, Solanas M, Escrich E, Cortés-Funes H, Colomer R. Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Breast Cancer Res Treat. 2002;72:203–19.
Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Oncol. 2004;24:1369–83.
Kong X, Ge H, Chen L, Liu Z, Yin Z, Li P, Li M. Gamma-linolenic acid modulates the response of multidrug-resistant K562 leukemic cells to anticancer drugs. Toxicol In Vitro. 2009;23:634–9.
Buckingham LE, Balasubramanian M, Safa AR, Shah H, Komarov P, Emanuele RM, Coon JS. Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diesters. Int J Cancer. 1996;65:74–9.
Ramesh G, Das UN, Koratkar R, Padma M, Sagar PS. Effect of essential fatty acids on tumor cells. Nutrition. 1992;8:343–7.
Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A. 1998;95:13182–7.
Rizzo MT, Regazzi E, Garau D, Akard L, Dugan M, Boswell HS, Rizzoli V, Carlo-Stella C. Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells. Cancer Res. 1999;59:5047–53.
Wolf LA, Laster SM. Characterization of arachidonic acid-induced apoptosis. Cell Biochem Biophys. 1999;30:353–68.
Cao Y, Dave KB, Doan TP, Prescott SM. Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res. 2001;61:8429–34.
Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002;62:6323–8.
Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002;62:4903–8.
Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000;60:6846–50.
Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, Lotan R, Fischer SM, Lippman SM. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000;92:1136–42.
Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, Lippman SM. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res. 2001;61:4879–84.
Maccarrone M, Ranalli M, Bellincampi L, Salucci ML, Sabatini S, Melino G, Finazzi-Agrò A. Activation of different lipoxygenase isozymes induces apoptosis in human erythroleukemia and neuroblastoma cells. Biochem Biophys Res Commun. 2000;272:345–50.
Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M, Mulshine JL. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J. 2001;15:2007–9.
Hong SH, Avis I, Vos MD, Martínez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 1999;59:2223–8.
Leaver HA, Bell HS, Rizzo MT, Ironside JW, Gregor A, Wharton SB, Whittle IR. Antitumour and pro-apoptotic actions of highly unsaturated fatty acids in glioma. Prostaglandins Leukot Essent Fatty Acids. 2002;66:19–29.
Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol. 2004;24:591–608.
Menendez JA, Colomer R, Lupu R. Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo’s hypothesis. Med Hypotheses. 2005;64:337–41.
Menendez JA, Colomer R, Lupu R. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med Hypotheses. 2005;64:342–9.
Nomura DK, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140:49–61.
Levine L. Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells. BMC Pharmacol. 2004;4:15.
Eitsuka T, Nakagawa K, Suzuki T, Miyazawa T. Polyunsaturated fatty acids inhibit telomerase activity in DLD-1 human colorectal adenocarcinoma cells: a dual mechanism approach. Biochim Biophys Acta. 1737;2005:1–10.
Eitsuka T, Nakagawa K, Miyazawa T. Dual mechanisms for telomerase inhibition in DLD-1 human colorectal adenocarcinoma cells by polyunsaturated fatty acids. Biofactors. 2004;21:19–21.
Jiang WG, Bryce RP, Mansel RE. Gamma linolenic acid regulates gap junction communication in endothelial cells and their interaction with tumour cells. Prostaglandins Leukot Essent Fatty Acids. 1997;56:307–16.
Sethi S, Eastman AY, Eaton JW. Inhibition of phagocyte-endothelium interactions by oxidized fatty acids: a natural anti-inflammatory mechanism? J Lab Clin Med. 1996;128:27–38.
Germain E, Chajes V, Cognault S, Lhuillery C, Bougnoux P. Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231; relationship to lipid peroxidation. Int J Cancer. 1998;75:578–83.
Shao Y, Pardini L, Pardini RS. Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1. Lipids. 1995;30:1035–45.
Chow SC, Jondal M. Ca2+ entry in T cells is activated by emptying the inositol 1,4,5-triphosphate sensitive Ca2+ pool. Cell Calcium. 1990;11:641–6.
Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yanker BA, Yuan J. Caspase-12 mediates endoplasmic reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature. 2000;403:98–103.
Huang ZH, Hii CS, Rathjen DA, Poulos A, Murray AW, Ferrante A. N-6 and N-3 polyunsaturated fatty acids stimulate translocation of protein kinase C alpha, beta I, beta II and –epsilon and enhance agonist-induced NADPH oxidase in macrophages. Biochem J. 1997;325(pt 2):553–7.
Peterson DA, Mehta N, Butterfield J, Husak M, Christopher MM, Jagarlapudi S, Eaton JW. Polyunsaturated fatty acids stimulate superoxide formation in tumor cells: a mechanism for specific cytotoxicity and a model for tumor necrosis factor? Biochem Biophys Res Commun. 1988;155:1033–7.
Chiu LC, Wan JM. Induction of apoptosis in HL-60 cells by eicosapentaenoic acid (EPA) is associated with downregulation of bcl-2 expression. Cancer Lett. 1999;145:17–27.
Albino AP, Juan G, Traganos F, Reinhart L, Connolly J, Rose DP, Darzynkiewicz Z. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. Cancer Res. 2000;60:4139–45.
Chen ZY, Istfan NW. Docosahexaenoic acid, a major constituent of fish oil diets, prevents activation of cyclin-dependent kinases and S-phase entry by serum stimulation in HT-29 cells. Prostaglandins Leukot Essent Fatty Acids. 2001;64:67–73.
Palakurthi SS, Fluckiger R, Aktas H, Changolkar AK, Shahsafaei A, Harneit S, Kilic E, Halperin JA. Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Res. 2000;60:2919–25.
Nishida M, Maruyama Y, Tanaka R, Kontani K, Nagao T, Kurose H. Gαi and Gαo are target proteins of reactive oxygen species. Nature. 2000;408:492–5.
Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N Jr, Ashe KH, Frautschy SA, Cole GM. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron. 2004;43:633–45.
Lukiw WJ, Cui J-G, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005;115:2774–83.
Comba A, Maestri DM, Berra MA, Garcia CP, Das UN, Eynard AR, Pasqualini ME. Effect of ω-3 and ω-9 fatty acid rich oils on lipoxygenases and cyclooxygenases enzymes and on the growth of a mammary adenocarcinoma model. Lipids Health Dis. 2010;9:112.
Liu B, Maher RJ, Hannun YA, Porter AT, Honn KV. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. J Natl Cancer Inst. 1994;86:1145–51.
Ding XZ, Tong WG, Adrian TE. 12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation. Int J Cancer. 2001;94:630–6.
Chen GG, Xu H, Lee JF, Subramaniam M, Leung KL, Wang SH, Chan UP, Spelsberg TC. 15-hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway. Int J Cancer. 2003;107:837–43.
Najid A, Beneytout JL, Tixier M. Cytotoxicity of arachidonic acid and of its lipoxygenase metabolite 15-hydroperoxyeicosatetraenoic acid on human breast cancer MCF-7 cells in culture. Cancer Lett. 1989;46:137–41.
Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SM. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A. 2003;100:9968–73.
Nixon JB, Kim KS, Lamb PW, Bottone FG, Eling TE. 15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer. Prostaglandins Leukot Essent Fatty Acids. 2004;70:7–15.
Kim SJ. Lipoxins formation by rat basophilic leukemia (RBL-1) cells. Res Commun Chem Pathol Pharmacol. 1990;68:159–74.
Stenke L, Edenius C, Samuelsson J, Lindgren JA. Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood. 1991;78:2989–95.
Chen Y, Hao H, He S, Cai L, Li Y, Hu S, Ye D, Hoidal J, Wu P, Chen X. Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Mol Cancer Ther. 2010;9:2164–74.
Gleissman H, Yang R, Martinod K, Lindskog M, Serhan CN, Johnsen JI, Kogner P. Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J. 2010;24:906–15.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, Part of Springer Nature
About this chapter
Cite this chapter
Das, U.N. (2020). Immune System, Inflammation, and Essential Fatty Acids and Their Metabolites in Cancer. In: Molecular Biochemical Aspects of Cancer. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0741-1_3
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0741-1_3
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0739-8
Online ISBN: 978-1-0716-0741-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)